Jaz­z's stock dips af­ter mid-stage fail in es­sen­tial tremor

Jazz Phar­ma­ceu­ti­cals said Thurs­day that the high­est dose of su­ve­cal­tamide failed a Phase 2b tri­al in es­sen­tial tremor, a neu­ro­log­i­cal con­di­tion that caus­es in­vol­un­tary shak­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.